Histologic classification of gliomas

Handbook of Clinical Neurology

Volumn 134, Issue , 2016, Pages 71-95

  Perry, Arie ^a   Wesseling, Pieter ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Astrocytoma; Ependymoma; Glioblastoma; Glioma; Glioneuronal tumor; Histopathology; Immunohistochemistry; Molecular diagnostics; Neuropathology; Oligodendroglioma

Indexed keywords

BRAIN TUMOR; CLASSIFICATION; GLIOMA; HISTOLOGY; HUMAN; PATHOLOGY; PROCEDURES;

BRAIN NEOPLASMS; GLIOMA; HISTOLOGICAL TECHNIQUES; HUMANS;

EID: 84976351823     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-12-802997-8.00005-0     Document Type: Chapter

References (99)

1. Aldape K., Zadeh G., Mansouri S., et al. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015, 129:829-848.
2. Barnard R.O., Geddes J.F. The incidence of multifocal cerebral gliomas. A histologic study of large hemisphere sections. Cancer 1987, 60:1519-1531.
3. Bechet D., Gielen G.G., Korshunov A., et al. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol 2014, 128:733-741.
4. Bielle F., Villa C., Giry M., et al. Chordoid gliomas of the third ventricle share TTF-1 expression with organum vasculosum of the lamina terminalis. Am J Surg Pathol 2015, 39:948-956.
5. Blumcke I., Wiestler O.D. Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 2002, 61:575-584.
6. Blumcke I., Giencke K., Wardelmann E., et al. The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies. Acta Neuropathol 1999, 97:481-490.
7. Brat D.J., Scheithauer B.W., Staugaitis S.M., et al. Third ventricular chordoid glioma: a distinct clinicopathologic entity. J Neuropathol Exp Neurol 1998, 57:283-290.
8. Brat D.J., Hirose Y., Cohen K.J., et al. Astroblastoma: clinicopathologic features and chromosomal abnormalities defined by comparative genomic hybridization. Brain Pathol 2000, 10:342-352.
9. Buczkowicz P., Bartels U., Bouffet E., et al. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol 2014, 128:573-581.
10. Burger P.C. What is an oligodendroglioma?. Brain Pathol 2002, 12:257-259.
11. Camelo-Piragua S., Jansen M., Ganguly A., et al. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol 2011, 70:110-115.
12. Capper D., Zentgraf H., Balss J., et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009, 118:599-601.
13. Cho H.Y., Lee M., Takei H., et al. Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, and chordoid meningioma. Appl Immunohistochem Mol Morphol 2009, 17:131-138.
14. Claes A., Idema A.J., Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol 2007, 114:443-458.
15. Colin C., Padovani L., Chappe C., et al. Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution. Neuropathol Appl Neurobiol 2013, 39:693-705.
16. Collins V.P., Jones D.T., Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015, 129:775-788.
17. Coons S.W., Johnson P.C., Scheithauer B.W., et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997, 79:1381-1393.
18. Dunbar E., Yachnis A.T. Glioma diagnosis: immunohistochemistry and beyond. Adv Anat Pathol 2010, 17:187-201.
19. Ellison D.W., Kocak M., Figarella-Branger D., et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 2011, 10:7.
20. Giannini C., Scheithauer B.W. Classification and grading of low-grade astrocytic tumors in children. Brain Pathol 1997, 7:785-798.
21. Giannini C., Scheithauer B.W., Burger P.C., et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 1999, 58:46-53.
22. Giannini C., Scheithauer B.W., Weaver A.L., et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 2001, 60:248-262.
23. Giannini C., Scheithauer B.W., Lopes M.B., et al. Immunophenotype of pleomorphic xanthoastrocytoma. Am J Surg Pathol 2002, 26:479-485.
24. Godfraind C. Classification and controversies in pathology of ependymomas. Childs Nerv Syst 2009, 25:1185-1193.
25. Hardee M.E., Zagzag D. Mechanisms of glioma-associated neovascularization. Am J Pathol 2012, 181:1126-1141.
26. Hirose T., Scheithauer B.W., Lopes M.B., et al. Tuber and subependymal giant cell astrocytoma associated with tuberous sclerosis: an immunohistochemical, ultrastructural, and immunoelectron and microscopic study. Acta Neuropathol 1995, 90:387-399.
27. Hsu C., Kwan G., Lau Q., et al. Rosette-forming glioneuronal tumour: imaging features, histopathological correlation and a comprehensive review of literature. Br J Neurosurg 2012, 26:668-673.
28. Ichimura K., Narita Y., Hawkins C.E. Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. Acta Neuropathol 2015, 129:789-808.
29. Ida C.M., Rodriguez F.J., Burger P.C., et al. Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol 2015, 25:575-586.
30. Jacques T.S., Eldridge C., Patel A., et al. Mixed glioneuronal tumour of the fourth ventricle with prominent rosette formation. Neuropathol Appl Neurobiol 2006, 32:217-220.
31. Johannessen A.L., Torp S.H. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 2006, 12:143-147.
32. Johnson M.W., Eberhart C.G., Perry A., et al. Spectrum of pilomyxoid astrocytomas: intermediate pilomyxoid tumors. Am J Surg Pathol 2010, 34:1783-1791.
33. Koelsche C., Wohrer A., Jeibmann A., et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 2013, 125:891-900.
34. Komori T., Scheithauer B.W., Anthony D.C., et al. Papillary glioneuronal tumor: a new variant of mixed neuronal-glial neoplasm. Am J Surg Pathol 1998, 22:1171-1183.
35. Komori T., Scheithauer B.W., Hirose T. A rosette-forming glioneuronal tumor of the fourth ventricle: infratentorial form of dysembryoplastic neuroepithelial tumor?. Am J Surg Pathol 2002, 26:582-591.
36. Korshunov A., Ryzhova M., Hovestadt V., et al. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 2015, 129:669-678.
37. Kros J.M. Grading of gliomas: the road from eminence to evidence. J Neuropathol Exp Neurol 2011, 70:101-109.
38. Kros J.M., Gorlia T., Kouwenhoven M.C., et al. Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 2007, 66:545-551.
39. Lehman N.L., Jorden M.A., Huhn S.L., et al. Cortical ependymoma. A case report and review. Pediatr Neurosurg 2003, 39:50-54.
40. Lellouch-Tubiana A., Boddaert N., Bourgeois M., et al. Angiocentric neuroepithelial tumor (ANET): a new epilepsy-related clinicopathological entity with distinctive MRI. Brain Pathol 2005, 15:281-286.
41. Li J.Y., Langford L., Adesina A., et al. The high mitotic count detected by phospho-histone H3 immunostain does not alter the benign behavior of angiocentric glioma. Brain Tumor Pathol 2012, 29:68-72.
42. Li D., Wang J.M., Li G.L., et al. Clinical, radiological, and pathological features of 16 papillary glioneuronal tumors. Acta Neurochir (Wien) 2014, 156:627-639.
43. Ligon K.L., Alberta J.A., Kho A.T., et al. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol 2004, 63:499-509.
44. Louis D.N., von Deimling A., Dickersin G.R., et al. Desmoplastic cerebral astrocytomas of infancy: a histopathologic, immunohistochemical, ultrastructural, and molecular genetic study. Hum Pathol 1992, 23:1402-1409.
45. Louis D.N., Ohgaki H., Wiestler O.D., et al. WHO Classification of Tumours of the Central Nervous System 2007, IARC Press, Lyon, France. 4th edn.
46. Louis D.N., Perry A., Burger P., et al. International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014, 24:429-435.
47. Louis D.N., Ohgaki H., Wiestler O.D., et al. WHO Classification of Tumours of the Central Nervous System 2016, IARC Press, Lyon, France. updated 4th edn.
48. Luyken C., Blumcke I., Fimmers R., et al. Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 2004, 101:146-155.
49. Majores M., von Lehe M., Fassunke J., et al. Tumor recurrence and malignant progression of gangliogliomas. Cancer 2008, 113:3355-3363.
50. Marburger T., Prayson R. Angiocentric glioma: a clinicopathologic review of 5 tumors with identification of associated cortical dysplasia. Arch Pathol Lab Med 2011, 135:1037-1041.
51. Miller C.R., Perry A. Glioblastoma. Arch Pathol Lab Med 2007, 131:397-406.
52. Ni H.C., Chen S.Y., Chen L., et al. Angiocentric glioma: a report of nine new cases, including four with atypical histological features. Neuropathol Appl Neurobiol 2015, 41:333-346.
53. Omuro A.M., Leite C.C., Mokhtari K., et al. Pitfalls in the diagnosis of brain tumours. Lancet Neurol 2006, 5:937-948.
54. Ostrom Q.T., Gittleman H., Liao P., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014, 16:iv1-iv63.
55. Osswald M., Jung E., Sahm F., et al. Brain tumour cells interconnect to a functional and resistant network. Nature 2015, 528:93-98.
56. Pajtler K.W., Witt H., Sill M., et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 2015, 27:728-743.
57. Patel A.P., Tirosh I., Trombetta J.J., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014, 344:1396-1401.
58. Peiffer J., Kleihues P. Hans-Joachim Scherer (1906-1945), pioneer in glioma research. Brain Pathol 1999, 9:241-245.
59. Perry A., Schmidt R.E. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 2006, 111:197-212.
60. Perry A., Giannini C., Scheithauer B.W., et al. Composite pleomorphic xanthoastrocytoma and ganglioglioma: report of four cases and review of the literature. Am J Surg Pathol 1997, 21:763-771.
61. Perry A., Scheithauer B.W., Macaulay R.J., et al. Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol 2002, 61:947-955.
62. Prabowo A.S., Iyer A.M., Veersema T.J., et al. BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors. Brain Pathol 2014, 24:52-66.
63. Prayson R.A. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity. Mod Pathol 1997, 10:304-310.
64. Prayson R.A. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry. Ann Diagn Pathol 1999, 3:11-18.
65. Prayson R.A., Suh J.H. Subependymomas: clinicopathologic study of 14 tumors, including comparative MIB-1 immunohistochemical analysis with other ependymal neoplasms. Arch Pathol Lab Med 1999, 123:306-309.
66. Preusser M., Budka H., Rossler K., et al. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms. Histopathology 2007, 50:365-370.
67. Preusser M., Capper D., Hartmann C., et al. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol 2011, 30:217-230.
68. Reuss D.E., Kratz A., Sahm F., et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 2015, 130:407-417.
69. Reuss D.E., Mamatjan Y., Schrimpf D., et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 2015, 129:867-873.
70. Reuss D.E., Sahm F., Schrimpf D., et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015, 129:133-146.
71. Riemenschneider M.J., Louis D.N., Weller M., et al. Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. Acta Neuropathol 2013, 126:21-37.
72. Rivera-Zengotita M., Yachnis A.T. Gliosis versus glioma? Don't grade until you know. Adv Anat Pathol 2012, 19:239-249.
73. Rodriguez F.J., Scheithauer B.W., Robbins P.D., et al. Ependymomas with neuronal differentiation: a morphologic and immunohistochemical spectrum. Acta Neuropathol 2007, 113:313-324.
74. Rodriguez F.J., Scheithauer B.W., Burger P.C., et al. Anaplasia in pilocytic astrocytoma predicts aggressive behavior. Am J Surg Pathol 2010, 34:147-160.
75. Rodriguez F.J., Perry A., Rosenblum M.K., et al. Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity. Acta Neuropathol 2012, 124:627-641.
76. Rodriguez F.J., Schniederjan M.J., Nicolaides T., et al. High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN). Acta Neuropathol 2015, 129:609-610.
77. Routhier C.A., Mochel M.C., Lynch K., et al. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol 2013, 44:2563-2570.
78. Sahm F., Reuss D., Koelsche C., et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 2014, 128:551-559.
79. Salvati M., D'Elia A., Brogna C., et al. Cerebral astroblastoma: analysis of six cases and critical review of treatment options. J Neurooncol 2009, 93:369-378.
80. Scheithauer B.W. Development of the WHO classification of tumors of the central nervous system: a historical perspective. Brain Pathol 2009, 19:551-564.
81. Scheithauer B.W., Fuller G.N., VandenBerg S.R. The 2007 WHO classification of tumors of the nervous system: controversies in surgical neuropathology. Brain Pathol 2008, 18:307-316.
82. Schniederjan M.J., Alghamdi S., Castellano-Sanchez A., et al. Diffuse leptomeningeal neuroepithelial tumor: 9 pediatric cases with chromosome 1p/19q deletion status and IDH1 (R132H) immunohistochemistry. Am J Surg Pathol 2013, 37:763-771.
83. Shakur S.F., McGirt M.J., Johnson M.W., et al. Angiocentric glioma: a case series. J Neurosurg Pediatr 2009, 3:197-202.
84. Sharma M., Ralte A., Arora R., et al. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins. Pathology 2004, 36:139-144.
85. Sharma M.C., Ralte A.M., Gaekwad S., et al. Subependymal giant cell astrocytoma - a clinicopathological study of 23 cases with special emphasis on histogenesis. Pathol Oncol Res 2004, 10:219-224.
86. Sottoriva A., Spiteri I., Piccirillo S.G., et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 2013, 110:4009-4014.
87. Stephen J.H., Sievert A.J., Madsen P.J., et al. Spinal cord ependymomas and myxopapillary ependymomas in the first 2 decades of life: a clinicopathological and immunohistochemical characterization of 19 cases. J Neurosurg Pediatr 2012, 9:646-653.
88. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
89. Sturm D., Witt H., Hovestadt V., et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012, 22:425-437.
90. Tamburrini G., Colosimo C., Giangaspero F., et al. Desmoplastic infantile ganglioglioma. Childs Nerv Syst 2003, 19:292-297.
91. Tarapore P.E., Modera P., Naujokas A., et al. Pathology of spinal ependymomas: an institutional experience over 25 years in 134 patients. Neurosurgery 2013, 73:247-255. discussion 255.
92. Tekkok I.H., Sav A. Anaplastic pleomorphic xanthoastrocytomas. Review of the literature with reference to malignancy potential. Pediatr Neurosurg 2004, 40:171-181.
93. Van Gompel J.J., Koeller K.K., Meyer F.B., et al. Cortical ependymoma: an unusual epileptogenic lesion. J Neurosurg 2011, 114:1187-1194.
94. VandenBerg S.R. Desmoplastic infantile ganglioglioma and desmoplastic cerebral astrocytoma of infancy. Brain Pathol 1993, 3:275-281.
95. Vincentelli C., Hwang S.N., Holder C.A., et al. The use of neuroimaging to guide the histologic diagnosis of central nervous system lesions. Adv Anat Pathol 2012, 19:97-107.
96. Weller M., Weber R.G., Willscher E., et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 2015, 129:679-693.
97. Wesseling P., van den Bent M., Perry A. Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015, 129:809-827.
98. Wiestler B., Capper D., Holland-Letz T., et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013, 126:443-451.
99. Zong H., Verhaak R.G., Canoll P. The cellular origin for malignant glioma and prospects for clinical advancements. Expert Rev Mol Diagn 2012, 12:383-394.